J&J Puts U.S. Coronary Stent Market Share At 15-18% Exiting Second Quarter
Johnson & Johnson estimates its share of the U.S. coronary stent market at 15-18% exiting the second quarter on the strength of its BX Velocity stent.
Johnson & Johnson estimates its share of the U.S. coronary stent market at 15-18% exiting the second quarter on the strength of its BX Velocity stent.